関連する実験動画
Updated: Jul 14, 2026

05:37
Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
レター:Palmieri et al. の「ファリシマブ硝子体内注射後のぶどう膜炎:症例報告」に関するコメント
Nicolas Nicolaou1, Despina Nicolaou1, Savvas Christou2
1Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.
Ocular immunology and inflammation
|December 29, 2025
まとめ
眼内炎症(IOI)はファリシマブ硝子体内注射後に発生する可能性があり、急性または遅延性で現れます。早期認識と迅速な管理は、良好な転帰のために重要です。
科学分野:
- 眼科学; 免疫学
背景:
- 硝子体内注射は網膜疾患の一般的な治療法です。ファリシマブはAng-2およびVEGF-Aを標的とする新しい二重特異性抗体です。無菌性眼内炎症(IOI)は硝子体内注射の潜在的な合併症です。
研究 の 目的:
- ファリシマブ硝子体内注射後の孤発性前部ぶどう膜炎および硝子体炎の提示と管理を記述すること。ファリシマブ治療に関連する主な特徴と潜在的な合併症を強調すること。
主な方法:
- ファリシマブ硝子体内注射後のIOI症例の後ろ向き分析。臨床的提示、発症時期、および管理戦略をレビューしました。
主要な成果:
- IOIの発症は注射後1~35日で、急性(5日未満)および遅延性(約14日)のパターンが観察されました。遅延性IOIはIV型過敏反応を示唆します。ファリシマブの二重阻害はヘルペス単純ウイルス再活性化のリスクを高める可能性があります。
結論:
- ファリシマブ後の無菌性IOIは、迅速な診断と管理が必要です。ヘルペス再活性化に対する注意が必要であり、予防的抗ウイルス療法が推奨されます。管理はIOIの重症度に合わせて調整し、感染を除外するための診断的タップを考慮する必要があります。
関連する概念動画
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

